FDA 预计将对帕金森病、创伤后应激障碍和 NF1 相关丛状神经纤维瘤的治疗方法以及两种新疫苗做出决定。 处方药使用者付费法案 (PDUFA)日期是指美国食品药品管理局 (FDA) 规定的审查新药申请 (NDA)或生物制品许可申请 (BLA)并最终决定是否批准上市的截止日期。审查期通常为药品申请被该机构接受后的 10 个月。对于优先审查的药品，审查期缩短为申请接受后的 6 个月。 FDA 正在审查 ...

Menveo is novel because it both covers four (A,C,W-135,Y) of the five major meningococcal serogroups and is immunogenic and safe when given as a four-dose schedule starting at 2 months of age 8.

LONDON, GREATER LONDON, UNITED KINGDOM, March 10, 2025 /EINPresswire / -- How Has the Menveo Market Performed in Recent Years, and What Does Its Future Hold? The Menveo market has experienced ...